source
- FDA issues new guidance for pharma on discussing unapproved drugs with payorsThe FDA has released guidance aimed at biopharma companies that are preparing to launch new therapies before they receive formal approval. The advice focuses on how companies can inform health-pla…
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.